NCT02856594View on ClinicalTrials.gov

Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

469

Participants

Timeline

Start Date

March 6, 2017

Primary Completion Date

February 11, 2022

Study Completion Date

February 16, 2022

Conditions
Postoperative DeliriumSleepAnesthesia
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine

DRUG

Placebo

Placebo

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Massachusetts General Hospital

OTHER

NCT02856594 - Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep | Biotech Hunter | Biotech Hunter